Education
About Us
Working with TipRanks
Follow Us
Schrodinger (SDGR)
NASDAQ:SDGR
SDGR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.60 - $28.47
Previous CloseN/A
Volume166.74K
Average Volume (3M)1.04M
Market Cap
$1.57B
Enterprise Value$1.13B
Total Cash (Recent Filing)$462.26M
Total Debt (Recent Filing)$114.31M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Nov 12, 2025EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding64,441,780
10 Day Avg. Volume1,092,217
30 Day Avg. Volume1,035,308
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.33
Price to Sales (P/S)6.75
P/FCF Ratio-8.51
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue4.75
Enterprise Value/Gross Profit8.12
Enterprise Value/Ebitda-6.40
Forecast
1Y Price Target
$25.50Price Target Upside19.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSDGR ended the period with $462.3mm in cash and equivalents.
Product LaunchSchrodinger's highly anticipated predictive tox software is now in beta testing with select biopharma customers and could be launched later this year or next year.
Strategic PartnershipsRecent Ph1 SGR-1505 data in hematologic malignancies and upcoming initial Ph1 SGR-3515 data in solid tumors, if positive, could further validate SDGR's platform and provide proof-of-concept for potential collaborations.
Bears Say
Growth UncertaintyThe software business serves as the core revenue driver, but there is uncertainty about its growth potential.
Macroeconomic HeadwindsIndustry macroeconomic headwinds have persisted, placing pressure on topline growth for the software segment.
Program TerminationSDGR announced termination of the SGR-2921 (CDC7) program for relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) due to 2 treatment-related deaths in the Ph1 dose escalation study.
Schrodinger News
SDGR FAQ
What was Schrodinger’s price range in the past 12 months?
Schrodinger lowest stock price was $16.60 and its highest was $28.47 in the past 12 months.
What is Schrodinger’s market cap?
Schrodinger’s market cap is $1.57B.
When is Schrodinger’s upcoming earnings report date?
Schrodinger’s upcoming earnings report date is Nov 12, 2025 which is in 34 days.
How were Schrodinger’s earnings last quarter?
Schrodinger released its earnings results on Aug 06, 2025. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.768 by $0.178.
Is Schrodinger overvalued?
According to Wall Street analysts Schrodinger’s price is currently Undervalued.
Does Schrodinger pay dividends?
Schrodinger does not currently pay dividends.
What is Schrodinger’s EPS estimate?
Schrodinger’s EPS estimate is -0.74.
How many shares outstanding does Schrodinger have?
Schrodinger has 64,441,780 shares outstanding.
What happened to Schrodinger’s price movement after its last earnings report?
Schrodinger reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.768. Following the earnings report the stock price went up 0.103%.
Which hedge fund is a major shareholder of Schrodinger?
Currently, no hedge funds are holding shares in SDGR
Schrodinger Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.50 (19.77% Upside)
$25.50 (19.77% Upside)
Blogger Sentiment
Bullish
SDGR Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 834.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.58%
12-Months-Change
Fundamentals
Return on Equity
-44.40%
Trailing 12-Months
Asset Growth
-0.02%
Trailing 12-Months
Company Description
Schrodinger
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
SDGR Company Deck
SDGR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and strong pipeline progress, alongside effective expense management and a robust cash position. However, these positives were offset by challenges in maintaining software gross margins, difficulties in the biotech segment, and continued net losses. The sentiment is balanced with notable progress and ongoing challenges.View all SDGR earnings summariesSDGR Stock 12 Month Forecast
Average Price Target
$25.50
▲(19.77% Upside)
Technical Analysis
Ownership Overview
2.40% Insiders
20.96% Mutual Funds
46.90% Other Institutional Investors
5.42% Public Companies and
Individual Investors